These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 15590241)

  • 21. Effect of secretin on children with autism: a randomized controlled trial.
    Dunn-Geier J; Ho HH; Auersperg E; Doyle D; Eaves L; Matsuba C; Orrbine E; Pham B; Whiting S
    Dev Med Child Neurol; 2000 Dec; 42(12):796-802. PubMed ID: 11132252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Double-Blind, Placebo-Controlled Trial of Secretin for the Treatment of Autistic Disorder.
    Owley T; Steele E; Corsello C; Risi S; McKaig K; Lord C; Leventhal BL; Cook Jr EH
    MedGenMed; 1999 Oct; ():E2. PubMed ID: 11104404
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Secretin and autism: a two-part clinical investigation.
    Chez MG; Buchanan CP; Bagan BT; Hammer MS; McCarthy KS; Ovrutskaya I; Nowinski CV; Cohen ZS
    J Autism Dev Disord; 2000 Apr; 30(2):87-94. PubMed ID: 10832772
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Opiate hypothesis in infantile autism? Therapeutic trials with naltrexone].
    Leboyer M; Bouvard MP; Launay JM; Recasens C; Plumet MH; Waller-Perotte D; Tabuteau F; Bondoux D; Dugas M
    Encephale; 1993; 19(2):95-102. PubMed ID: 8275903
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized, double-blind, placebo-controlled trial of porcine versus synthetic secretin for reducing symptoms of autism.
    Unis AS; Munson JA; Rogers SJ; Goldson E; Osterling J; Gabriels R; Abbott RD; Dawson G
    J Am Acad Child Adolesc Psychiatry; 2002 Nov; 41(11):1315-21. PubMed ID: 12410073
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability.
    Chez MG; Burton Q; Dowling T; Chang M; Khanna P; Kramer C
    J Child Neurol; 2007 May; 22(5):574-9. PubMed ID: 17690064
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Secretin for the treatment of autism.
    McQueen JM; Heck AM
    Ann Pharmacother; 2002 Feb; 36(2):305-11. PubMed ID: 11847953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacotherapy to control behavioral symptoms in children with autism.
    Doyle CA; McDougle CJ
    Expert Opin Pharmacother; 2012 Aug; 13(11):1615-29. PubMed ID: 22550944
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Guanfacine in children with autism and/or intellectual disabilities.
    Handen BL; Sahl R; Hardan AY
    J Dev Behav Pediatr; 2008 Aug; 29(4):303-8. PubMed ID: 18552703
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Double-blind placebo-controlled trial of secretin: effects on aberrant behavior in children with autism.
    Carey T; Ratliff-Schaub K; Funk J; Weinle C; Myers M; Jenks J
    J Autism Dev Disord; 2002 Jun; 32(3):161-7. PubMed ID: 12108617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Children with autistic spectrum disorders. I: comparison of placebo and single dose of human synthetic secretin.
    Levy SE; Souders MC; Wray J; Jawad AF; Gallagher PR; Coplan J; Belchic JK; Gerdes M; Mitchell R; Mulberg AE
    Arch Dis Child; 2003 Aug; 88(8):731-6. PubMed ID: 12876177
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Medical treatment of pervasive developmental disorders].
    Fuentes J; Gallano I
    Rev Neurol; 2001 Aug 1-15; 33(3):208-10. PubMed ID: 11588711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risperidone: new indication. Behavioural disorders in children with autism or mental disabilities: no progress.
    Prescrire Int; 2006 Apr; 15(82):43-5. PubMed ID: 16602211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacotherapy of irritability in pervasive developmental disorders.
    Stigler KA; McDougle CJ
    Child Adolesc Psychiatr Clin N Am; 2008 Oct; 17(4):739-52, vii-viii. PubMed ID: 18775367
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Social and communication behaviours in infants and toddlers with autism and pervasive developmental disorder-not otherwise specified.
    Fodstad JC; Matson JL; Hess J; Neal D
    Dev Neurorehabil; 2009 Jun; 12(3):152-7. PubMed ID: 19466623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Repeated doses of porcine secretin in the treatment of autism: a randomized, placebo-controlled trial.
    Roberts W; Weaver L; Brian J; Bryson S; Emelianova S; Griffiths AM; MacKinnon B; Yim C; Wolpin J; Koren G
    Pediatrics; 2001 May; 107(5):E71. PubMed ID: 11331721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transdermal secretin for autism - a case report.
    Lamson DW; Plaza SM
    Altern Med Rev; 2001 Jun; 6(3):311-3. PubMed ID: 11410075
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures.
    Posey DJ; Aman MG; McCracken JT; Scahill L; Tierney E; Arnold LE; Vitiello B; Chuang SZ; Davies M; Ramadan Y; Witwer AN; Swiezy NB; Cronin P; Shah B; Carroll DH; Young C; Wheeler C; McDougle CJ
    Biol Psychiatry; 2007 Feb; 61(4):538-44. PubMed ID: 17276750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study.
    Wasserman S; Iyengar R; Chaplin WF; Watner D; Waldoks SE; Anagnostou E; Soorya L; Hollander E
    Int Clin Psychopharmacol; 2006 Nov; 21(6):363-7. PubMed ID: 17012983
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders.
    Posey DJ; McDougle CJ
    Harv Rev Psychiatry; 2000; 8(2):45-63. PubMed ID: 10902094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.